

ASPIRE

Advancing Science Through Pfizer –
Investigator Research Exchange



**PATIENTS
FIRST**
Think Big. Take Pride. No Excuses.

Pfizer is proud to introduce the

Patients First: Inflammation ASPIRE 2018 RESEARCH AWARDS

A Competitive Grants Programme supported by Pfizer for investigators throughout wider Europe, Israel, Turkey, Russia, Australia, New Zealand, Japan and South Korea.

Pfizer invites investigators to apply for the Patients First: Inflammation ASPIRE 2018 Awards through submission of research proposals with the primary objective to increase understanding of:

- The effect of inhibition of the JAK–STAT pathway by targeting JAK on specific clinical effects, looking at efficacy and/or safety outcomes in rheumatoid arthritis (RA), ulcerative colitis (UC) and psoriatic arthritis (PsA)
- The role of the JAK–STAT pathway in inflammation in PsA

Advances in science and medicine should translate into tangible clinical benefit in the short and long term. With this in mind, proposals should aim to describe the clinical value, the proposed research and its outcomes will add to patients' lives. Innovative patient approaches in research design and/or research leading to tangible positive outcomes for patients will be prioritised.

An independent committee of European medical experts in the field of Inflammation will review the research proposals and select the grant recipients.



For more information please visit www.aspireresearch.org

AREAS OF FOCUS

The programme focuses on clinical research in RA, UC and PsA, as well as translational research in PsA, and may include, but is not limited to the following topics:

Rheumatology

1. Treatment Optimisation in Rheumatoid Arthritis

- Treatment strategies in RA patients in sustained remission whilst on JAK inhibitor treatment
- Optimisation of management of RA patients, treated with JAK inhibitors, such as, but not limited to, monotherapy, concomitant treatment tapering or withdrawal (glucocorticoids, csDMARDs)
- Management of JAK inhibitor treatment in patients with co-morbidities, such as (but not limited to) infections (herpes zoster [HZ], other), interstitial lung disease
 - HZ immunisation prior to JAK inhibitor treatment
- Impact of JAK inhibitor treatment on pain (CNS/peripheral)
- Assessment of adherence and compliance in patients treated with JAK inhibitors

2. Role of JAK Pathway in Psoriatic Arthritis & Impact of JAK Inhibition on a Broad Range of Clinical Outcomes

- The role of JAK pathway in the pathophysiology and immunology of PsA
- The role of JAK–STAT inhibition with respect to pain and fatigue
- Effect of JAK–STAT inhibition on dactylitis and/or anesthesias
- Mechanistic understanding of JAK–STAT signalling on structural progression
- Effect of JAK–STAT inhibition in monotherapy

Inflammatory Bowel Disease

Enhancing the Understanding of the Clinical Profile of JAK Inhibitors in the Treatment of UC Patients*

- Management of the risk of HZ with vaccination in UC patients treated with JAK inhibitors
- Evaluation of lipid elevations with JAK inhibitors in UC patients, including the MOA of such potential effects
- Effect of JAK inhibitors on extra-intestinal manifestations in UC patients
- Effects of JAK inhibitors on hospitalisation and surgery rate, their respective causes and post-surgery complications
- Evaluation of risk for adenoma/dysplasia/colon cancer rate of patients treated with JAK inhibitors

**Strong preference will be given to studies that utilise the ECCO UR-CARE platform for capturing IBD patients' records.*

Pfizer is funding awards up to €1.5–2.0 million for exceptional proposals in multicentre, multinational clinical studies in RA. All other awards in RA will vary depending on the research question. Funding in PsA and UC will also depend on the research question, with maximum awards of up to €200,000 for clinical proposals and up to €80,000 for translational research in PsA. It is expected that the results will be presented at scientific meetings and published in peer-reviewed journals.

APPLICATION SUBMISSION START: JANUARY 15th 2018
APPLICATION DEADLINE: MARCH 23rd 2018

The ASPIRE 2018 award applications are possible for any investigator. To be eligible for an investigator award, an applicant must hold an MD, PhD, PharmD or the equivalent and must reside in wider Europe, Israel, Turkey, Russia, Australia, New Zealand, Japan or South Korea.



For more information please visit www.aspireresearch.org